| 李勇,李凯琅,曹葆强.糖类抗原19-9在三种胆囊良恶性疾病中的表达研究[J].安徽医药,2016,20(10):1926-1928. |
| 糖类抗原19-9在三种胆囊良恶性疾病中的表达研究 |
| Anormaly expression of serum tumor marker CA 19-9 on three benign and malignant gallbladder diseases |
| 投稿时间：2016-05-18 |
| DOI： |
| 中文关键词: 肿瘤指标 CA19-9 急性结石性胆囊炎 黄色肉芽肿性胆囊炎 胆囊癌 |
| 英文关键词: Tumor marker CA19-9 Acute calculous cholecystitis Xanthogranulomatous cholecystitis Gallbladder cancer |
| 基金项目: |
|
| 摘要点击次数: 2358 |
| 全文下载次数: 742 |
| 中文摘要: |
| 目的 研究血清糖类抗原19-9(CA19-9)在胆囊良性疾病急性结石性胆囊炎、黄色肉芽肿性胆囊炎和恶性疾病胆囊癌患者血清中的异常表达,探讨CA19-9在上述三种疾病的鉴别诊断价值。方法 回顾性研究血清CA19-9异常的急性结石性胆囊炎、黄色肉芽肿性胆囊炎和胆囊癌病例各50例,分别设为研究1组、研究2组、研究3组。比较三组治疗前后血清CA19-9值。结果 研究1组治疗前CA19-9(312.76±30.34) U·mL-1,治疗后1个月基本恢复正常(20.73±8.61) U·mL-1,差异有统计学意义(P﹤0.05)；研究2组治疗前血清CA19-9(119.61±13.67) U·mL-1,治疗6个月后基本恢复正常(26.34±10.25) U·mL-1,差异有统计学意义(P﹤0.05)；研究3组治疗前血清CA19-9(459.56±86.21)U·mL-1,治疗后随访6个月(212.71±40.11) U·mL-1,死亡7例,随访12个月仅少数恢复正常 (251.53±50.56) U·mL-1,死亡16例,差异无统计学意义(P>0.05)。结论 三种胆囊良恶性疾病的血清CA19-9都能异常表达,但各自有其特点和临床意义,血清CA19-9是肿瘤指标,也可以是炎性指标,可以根据其表达特点加以鉴别疾病。 |
| 英文摘要: |
| Objective To study anormaly expression of serum tumor marker carbohydrate antigen 19-9 (CA19-9) on acute calculous cholecystitis (ACC),xanthogranulomatous cholecystitis (XGC) and gallbladder cancer (GC),and to explore the diagnostic significance of CA19-9 in the three diseases.Methods A retrospective study was made of 150 cases with high CA19-9 level which were assigned into three groups.Fifty cases with ACC were studied as experimental group 1,0 cases with XGC were studied as experimental group 2 and 50 cases with GC were studied as experimental group 3.Statistical software SSPS was applied to analyze the results,comparing the data collected from three groups.Results There was significant difference in CA19-9 level before and one month after the treatment in experimental group 1 (312.76±30.34) U·mL-1 vs(20.73±8.61) U·mL-1,P＜0.05);there was significant difference in CA19-9 level before and 6 months after the treatment in experimental group 2 (119.61±13.67)U·mL-1 vs (26.34±10.25) U·mL-1,P﹤0.05);in eperimental group 3 the level of CA19-9 was(459.56±86.21)U·mL-1 and there was no significant differences in CA19-9 level and mortality between 6-month follow-up and 12-month follow-up (212.71±40.11)U·mL-1 vs (251.53±50.56) U·mL-1,7 deaths vs 16 deaths,P>0.05).Conclusions Patients with ACC,XGC and GC all could have high levels of CA19-9,which show different characteristics and clinical significances.CA19-9 is not only a tumor marker but also an inflammation marker in gallbladder diseases,therefore,we could distinguish them on the basis of clinical characteristics. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
